HER2 Amplification
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer (NCT06328738) | Enliven Therapeutics | 2024-05-30 |
| ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (NCT05650879) | Enliven Therapeutics | 2023-03-20 |
Track HER2 Amplification automatically
Every clearance here is in the API, with alerts when new ones post.